BY Nick Manes
Biopharmaceutical company Tetra Therapeutics Inc. announced this week that it has a definitive agreement to sell to
a Japanese firm in a deal that could reach $500 million, according to a statement.
Tetra Therapeutics, which develops drugs for people suffering from Fragile X syndrome, Alzheimer’s disease,
traumatic brain injury and other brain disorders, has finalized a 2018 agreement with the Japanese company.
Under the terms of the merger agreement, Tetra will become a wholly owned subsidiary of Shionogi, and Shionogi
will have global rights to all Tetra compounds. Based on the achievement of certain predetermined regulatory and
commercial milestones the total transaction value may be up to $500 million, the companies said in a news release.
Read the full article on Crain’s website.